Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ICON to Acquire Clinical Trial Services Division of Cross Country Healthcare Inc

Published: Thursday, February 07, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
Acquisition expands ICON’s global resourcing, FSP and safety capabilities.

ICON plc, has announced that it has agreed, subject to certain closing conditions, to acquire the Clinical Trial Services Division of Cross Country Healthcare, Inc., for a cash consideration of $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones. The transaction is expected to close within the next 30 days.

Cross Country Healthcare’s Clinical Trial Services Division includes leading US resourcing providers, ClinForce and Assent Consulting, whose services include contract staffing, permanent placement and functional service provision.

The division also includes AKOS, a leading US and EU provider of pharmacovigilance and drug safety services.

ClinForce and Assent will be combined with ICON’s FSP division, DOCS, creating a leader in global resourcing and FSP, while AKOS will enhance the services offered by ICON’s medical and safety services team.

Commenting on the acquisition, Ciaran Murray, CEO at ICON plc, said: “The demand for flexible resourcing solutions continues to grow as biopharma companies employ a range of outsourcing models to meet their development goals more efficiently. The ClinForce and Assent businesses will significantly expand our resourcing and FSP capabilities in the US and, when combined with DOCS strong European footprint and growing emerging markets presence, gives us the ability to deliver truly global resourcing solutions. Additionally, AKOS enhances our expertise in the areas of pharmacovigilance and drug safety consulting, which are increasingly important capabilities required by our clients.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ICON Creates New Global Innovation Hub in Ireland
Global Innovation Hub will create 200 Scientific, IT and Business jobs in Ireland.
Thursday, February 05, 2015
ICON Selected by the FDA to Develop New PRO Measure for HABP Trials
New PRO measure being developed in conjunction with the FNIH Biomarkers Consortium.
Thursday, November 13, 2014
ICON Launches New Analytics Service for Advanced Medical Review of Laboratory Data
ICONIK Labs allows visualization, analysis and reporting on laboratory data in real time.
Tuesday, November 19, 2013
ICON Announces Appointment to Board of Directors
ICON plc today announced the appointment of Professor William Hall as a non-executive director.
Friday, February 22, 2013
ICON Launches New Medical Imaging Solution for Early Phase Trials
Streamlined early phase offering designed to support faster decision making.
Thursday, October 25, 2012
ICON Selected by Shire as Global Strategic Partner
Global strategic partner for clinical research and central laboratory services.
Monday, January 23, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!